MD · Pediatrix Medical Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $240.79M | $238.44M | $227.54M | $231.40M | $263.36M | $248.95M |
| Total Operating Expenses | $1.71B | $2.08B | $1.99B | $1.80B | $1.71B | $1.64B |
| D&A | $21.83M | $32.23M | $36.17M | $35.64M | $32.15M | $28.44M |
| Operating Income | $208.81M | ($68.71M) | $7.32M | $172.69M | $202.92M | $98.13M |
| Interest Expense | $35.97M | $40.74M | $42.08M | $39.70M | $68.72M | $110.48M |
| Income Tax | $51.04M | ($2.27M) | $12.05M | $18.81M | $27.24M | $16.73M |
| Net Income | $165.39M | ($99.07M) | ($60.41M) | $66.33M | $130.96M | ($796.49M) |
| EPS - Basic | $1.97 | ($1.19) | $0.73 | $0.79 | $1.54 | ($9.55) |
| EPS - Diluted | $1.94 | ($1.19) | $0.73 | $0.79 | $1.53 | ($9.55) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $375.24M | $229.94M | $73.26M | $9.82M | $387.39M | $1.12B |
| Accounts Receivable | $229.66M | $259.99M | $272.31M | $296.79M | $301.77M | $241.93M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $37.22M | $46.43M | $34.59M | $31.86M | $36.65M | $59.77M |
| Current Assets | $763.51M | $639.61M | $483.45M | $427.99M | $840.56M | $1.55B |
| Total Assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B | $3.35B |
| Current Liabilities | $458.91M | $434.11M | $388.95M | $426.98M | $427.37M | $444.33M |
| Long-term Debt | - | $611.20M | $622.20M | $637.20M | $989.70M | $1.70B |
| Total Liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B | $2.60B |
| Stockholders' Equity | $865.85M | $764.94M | $849.06M | $891.63M | $896.49M | $747.49M |
| Retained Earnings | ($83.15M) | ($248.54M) | $149.47M | ($89.06M) | ($155.39M) | ($286.35M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $271.09M | $206.57M | $137.32M | $166.94M | $76.74M | $204.62M |
| Investing Cash Flow | ($18.30M) | ($35.41M) | ($48.18M) | ($56.95M) | ($53.07M) | $815.51M |
| Financing Cash Flow | ($107.49M) | ($14.48M) | ($25.71M) | ($487.55M) | ($760.12M) | ($4.16M) |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | 23.6% | - | - | 22.1% | 17.2% | - |
| Return on assets | 7.4% | -4.6% | -2.7% | 2.8% | 4.8% | -23.8% |
| Return on equity | 19.1% | -13.0% | -7.1% | 7.4% | 14.6% | -106.6% |
| Return on invested capital | - | -3.9% | 0.4% | 8.8% | 8.9% | 3.2% |
| Liquidity | ||||||
| Current ratio | 1.66 | 1.47 | 1.24 | 1.00 | 1.97 | 3.49 |
| Quick ratio | 1.66 | 1.47 | 1.24 | 1.00 | 1.97 | 3.49 |
| Cash ratio | 0.82 | 0.53 | 0.19 | 0.02 | 0.91 | 2.53 |
| Leverage | ||||||
| Debt / Equity | - | 0.80 | 0.73 | 0.71 | 1.10 | 2.27 |
| Debt / Assets | - | 0.28 | 0.28 | 0.27 | 0.36 | 0.51 |
| Debt / EBITDA | - | - | 14.31 | 3.06 | 4.21 | 13.43 |
| Interest coverage | 5.8x | -1.7x | 0.2x | 4.4x | 3.0x | 0.9x |
| Equity multiplier | 2.59 | 2.81 | 2.61 | 2.63 | 3.04 | 4.48 |
| Liabilities / Assets | 0.61 | 0.64 | 0.62 | 0.62 | 0.67 | 0.78 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 11.0x | - | 12.7x | 18.8x | 17.8x | - |
| P / B | 2.1x | 1.4x | 0.9x | 1.4x | 2.6x | 2.7x |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | 6.3x | - | 30.2x | 9.0x | 12.5x | 20.7x |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | -95.8% | -14.9% | 106.8% | - |
| Net income growth (YoY) | - | -64.0% | - | -49.3% | - | 46.8% |
| EPS growth (YoY) | - | - | -7.6% | -48.4% | - | 46.8% |
| EPS CAGR (3y) | 34.9% | - | - | - | -19.5% | - |
| EPS CAGR (5y) | - | - | -24.3% | -25.5% | -15.2% | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 13.2% | -9.9% | -4.8% | -0.5% | 19.9% | -50.1% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Hospitals
Comparing Pediatrix Medical Group against the 3 most active filers in the same SIC group.